Track topics on Twitter Track topics that are important to you
US-based biotechnology firm Peloton Therapeutics has started dosing patients in its Phase II clinical trial of PT2385 for the treatment of kidney cancer caused by von Hippel-Lindau (VHL) disease.
The Leading At-Home Fitness Solution Chooses Gradifi’s SLP Plan™ Gradifi, one of the leaders in student loan pay down benefit programs for U.S. employers, today ann...
Life Sciences Jobs ...
Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing novel small molecule cancer therapies, announced today it has entered into an exclusive a...
Study conducted in collaboration with the National Cancer Institute Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing novel small molec...
Company to Use Funding to Expand Offering and Retail Presence Peloton, the technology company revolutionizing the fitness industry through its indoor cycling bike and studio c...
SummaryPeloton Therapeutics Inc Peloton is a clinicalstage biotechnology company with a focus on developing novel therapies targeting renal and other cancers. The company's lead product, PT2385, is a ...
During eukaryotic transcription, RNA polymerase (RNAP) translocates along DNA molecules covered with nucleosomes and other DNA binding proteins. Though the interactions between a single nucleosome and...
Peloton Therapeutics is a drug discovery and development company focused on advancing first-in-class small molecule therapies for cancer and other life-threatening diseases. Initi...
We have published hundreds of The Peloton news stories on BioPortfolio along with dozens of The Peloton Clinical Trials and PubMed Articles about The Peloton for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Peloton Companies in our database. You can also find out about relevant The Peloton Drugs and Medications on this site too.